1 / 27

Jaf1a

1.1 MILLION WWE. Mark Yerby M.D., M.P.H.. WOMEN with EPILEPSY HAVE ... AEDs imperative for WWE. Incomplete information hinders effective medical management ...

Rider
Télécharger la présentation

Jaf1a

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Complications with the Use of Anticonvulsants in Pregnancy

  2. PREVALENCE of EPILEPSY • 3.2 MILLION AMERICANS • 50 % WOMEN • 40 % CHILDBEARING AGE • 1.1 MILLION WWE

  3. WOMEN with EPILEPSY HAVE UNIQUE PROBLEMS • SEIZURES EXACERBATED by HORMONES • INFERTILITY • CONTRACEPTIVE FAILURE • COSMETIC EFFECTS • HIGH RISK PREGNANCIES

  4. Difficulties Associated with AED • Metabolism of Hormonal Contraceptives Accelerated by AED • Concentration of AED Decline in Pregnancy • First Trimester Exposure is Associated with Risk of Malformations • Competitive Inhibitors of Vitamin K • Transfer to Breast Milk

  5. Clinical Dilemma • Drugs generally contraindicated in pregnancy • WWE unable to stop AED • Increases risk of seizures • Injury • Miscarriage • Developmental delay • Loss of Job or Driving Privileges • Risk of cognitive decline

  6. Safety of New AED ? • 8 New AED since 1993 - Little Empirical Data • No Malformations in Monotherapy • Felbamate: 9+ Pregnancies • Gabapentine: 100+ Pregnancies • Lamotrigine: 189+ Pregnancies • Oxcarbazepine 23 + Pregnancies • Topiramate: 5 + Pregnancies • Tiagabine: 29 + Pregnancies • Trileptal: 12 + Pregnancies • Zonisamide 26 + Pregnancies

  7. Hormonal Contraceptive Failure • Enzyme Inducing AED • CBZ, DPH, PB, PRM, TOP • Increase Clearance of Co-medication • O.C. - Norplant - Depo-Provera • All have Reported Failures w/ AED

  8. AED Levels Decline as Pregnancy Progresses • Even in the Face of Constant & Sometimes Increased Dosage • Dissociation of Plasma Protein Binding • Total Levels Decline for all “older” AED • Free Levels do not Decline at the same Rate • Different AED Decline at Different Rates • Levels Rise in the Post Partum Period

  9. Falls - Injury Premature Labor Miscarriage Suppression Fetal Heart Rate Epilepsy in the Child Abruptio Placenta Intracranial Hemorrhage Perinatal Seizures Infant Mortality Developmental Delay Significance of Declining AED1/4 - 1/3 of Women Increase Seizures

  10. Risk of Status in Pregnancy • Status fortunately uncommon • Abrupt Cessation of AED Increases the Risk • 29 reported cases (Teramo & Hiilesmaa 1982) • 9 Maternal • 14 Fetal Deaths

  11. ADVERSE PREGNANCY OUTCOMES • DECEASED VIABILITY • Increased Fetal Loss & Infant Mortality • DECREASED GROWTH • Increased Small for Dates • NEONATAL COMPLICATIONS • Hemorrhage • MALDEVELOPMENT • Malformations, Anomalies, Developmental Delay

  12. Congenital Malformations • Reported with all AED • RR = 2 - 2.4 • 4 - 6 % • Most Common • Oro - Facial Clefts • Midline Heart Defects • Skeletal Defects

  13. Malformations • Risk Factors • Polytherapy • High Plasma Concentrations • Mechanisms - Toxic Metabolites • Epoxide Metabolites • Free Radial Formation

  14. Pharmacokinetics / Pharmacogenetics & Teratogenicity • Metabolites of AED are associated with Malformations. • Specific AED are metabolized by specific pharmacokinetic pathways. • The pharmacogenetics of individual persons dictates the effectiveness of the metabolism . • Teratogenicity occurs when genetic factors leading to poor metabolism fail to eliminate toxic intermediaries.

  15. Neural Tube Defects & AED Exposure • Some AED Associated with Increased Risk of Neural Tube Defects • Valproic Acid 1 - 2 % • (Omtzigt 1992 NTD rate with VPA = 5.4 %) • Carbamazepine 0.5 %

  16. Neural Tube Defects Association with Valproic Acid • SUPPORTING EVIDENCE • Case Series, Case Reports • Dose Response Effect, (Omtzigt 1992) • Mean dose 1641 mg. with NTD • Mean does 941 mg. without NTD • PROBLEMS • No Controlled Studies • Possible Association Primary Epilepsy

  17. DEVELOPMENTAL DELAY • PREVALENCE = 1.2 - 6.2 % • RISK FACTORS • Low Maternal IQ • Polytherapy • Poor Maternal Seizure Control

  18. NEONATAL HEMORRAGE • DESCRIBED with: PB, PRM, PHT, CBZ, ETH • FIRST 24 HOURS • HIGH MORTALITY • AED Competitive Inhibitors Vit. K • PREVENTION: • Maternal Vit. K 10 mg/ day last Week Pregnancy

  19. BREAST FEEDING • Milk / Plasma Ratio < 1 • Low Volumes Consumed • Milk Concentration Inverse of Protein Binding • Exceptions: • Lamictal M / P > 1 • Topiramate M / P < 1 • Zonisamide M / P = 0.9

  20. AED Kinetics in Plasma & Breast Milk • Breast Milk / PlasmaElimination Half-life (hour) • AnticonvulsantConcentration Ratio AdultNeonate % Protein Binding • Carbamazepine 0.4 - 0.6 8 - 25 8 - 28 75 • Ethosuximide 0.9 40 - 60 40 < 10 • Phenobarbital 0.4 - 0.6 75 - 126 45 - 500 45 • Phenytoin 0.2 - 0.4 12 - 50 15 - 105 90 • Primidone 0.7 - 0.9 4 - 12 7 - 60 < 20 • Valproic Acid 0.01 6 - 18 30 - 60 90

  21. AED Kinetics “New AED” • Breast Milk / PlasmaElimination Half-life (hour) • AnticonvulsantConcentration Ratio AdultNeonate % Protein Binding • Felbamate ? 14 -22 ? 24 - 35 • Gabapentine ? 5 - 8 ? 0 • Lamotrigine 0.4 - 0.7 24 ? 55 • Levetiracetam ? 6- 8 ? < 10 • Oxcarbazepine 0.5 8 - 10 ? 45 • Tiagabine ? 4.5 - 13 ? 95 • Topiramate < 1 19 - 23 ? 15 • Zonisamide 0.9 50 -60 ?

  22. Pharmacokinetics “Older” AED in Pregnancy • Percent Decrease • Total Level Percent Free Fraction • Anticonvulsant by 3rd Trimester Normal Maternal Neonatal • Carbamazepine 40% 22% 25% 35% • Ethosuximide ? 90% ? ? • Phenobarbital 55% 51% 58% 66% • Phenytoin 56% 9% 11% 13% • Primidone 55% ? ? ? • Derived Phenobarbital 70% 75% 80% ? • Valproic Acid 50% 9% 15% 19%

  23. Conclusions • Women with Epilepsy Cannot Safely Stop AED • Increased Risk of Seizures • AED can Increase Risks • Malformations • Neonatal hemorrhage • ? Developmental Delay • Incomplete Information on “Older” Pre 1993 AED • Scanty Information on “Newer” Post 1993 AED

  24. Obstacles to Studies in Women Potential effect on fertility Potential effect on fetal anatomical development Potential effect on cognitive development Consequence of Lack of Data No safety information No knowledge of risks for fetal exposure Little opportunity for risk reduction Exclusion of Women from Clinical Trials

  25. Methods for Ethical Collection of Pharmacokinetic Data in Women with Epilepsy • Well designed informed consent • Trials of AED effect on Hormonal Contraceptives and Vitamin K • do not require pregnancy • Trials of Kinetics in Pregnancy and Breast Milk • Study non-human primates • Use unplanned pregnancies • Indemnify manufacturer and investigator

  26. Better use of Post Marketing Experience • Many women will use AED post market • Systematic surveillance projects • Target Pharmacies / Prescriptions / Specialists • Current Registries used as models • Use CDC or CROs for surveillance • Determine threshold signal for intervention • Regular reporting of cumulative experience

  27. Summary • AEDs contribute to risks: • infertility, contraceptive failure, adverse pregnancy outcome • AEDs imperative for WWE • Incomplete information hinders effective medical management • Improved premarketing clinical trials and post marketing surveillance • Permit selection of safer drugs • Clinicians know what to expect in pregnancy

More Related